Alamar Biosciences, Inc.
Key Metrics
Market Snapshot
About
Alamar Biosciences, Inc. (ALMR) is a Fremont, California-based biotechnology company best known for developing advanced proteomics technology for disease research and detection. The company is a specialist in proteomic liquid biopsy, creating platforms and tools designed to identify protein biomarkers with high sensitivity.
The company's primary offering is the NULISA technology platform. This system is engineered for the detection and quantification of protein biomarkers at ultra-high sensitivity levels and can analyze multiple biomarkers simultaneously. To bring this technology to researchers, Alamar sells its fully automated ARGO high throughput (HT) System, along with related consumables and services. This integrated platform supports the entire workflow of biomarker analysis, from initial discovery and translational research to potential future diagnostic applications.
Alamar's products are utilized by a global customer base for research in critical disease areas such as immunology, neurology, and oncology. Its clients include research and academic institutions, biopharmaceutical companies, contract research organizations, and service laboratories. The company markets its platform internationally, with operations spanning the United States, Europe, the Middle East, Africa, and the Asia Pacific region. Founded in 2018, Alamar Biosciences focuses on enabling earlier and more precise detection of diseases through its proprietary proteomics tools.